New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Bolt Biotherapeutics, Inc. (BOLT) vs Seres Therapeutics, Inc. (MCRB)
- Bolt Biotherapeutics, Inc. BOLT 4.91 −2.96%
- Seres Therapeutics, Inc. MCRB 1.24 −6.77%
Bolt Biotherapeutics, Inc. and Seres Therapeutics, Inc. are both Biotechnology companies. Bolt Biotherapeutics, Inc. and Seres Therapeutics, Inc. are of similar size ($13.6M and $13.2M). Bolt Biotherapeutics, Inc. has the higher net margin (−611.5% vs −2,209.6%) and the higher return on invested capital (−154.8% vs −1,267.8%). Across the 13 metrics below, Bolt Biotherapeutics, Inc. leads on 9 and Seres Therapeutics, Inc. on 4.
Valuation
Profitability
| Metric | BOLT | MCRB | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 70.18% |
| Operating margin | (654.53%) | (3,656.89%) | 0.00% |
| Net margin | (611.47%) | (2,209.55%) | 0.00% |
| Free cash flow margin | (655.72%) | — | 0.00% |
| Return on equity | (127.96%) | (144.35%) | (51.58%) |
| Return on assets | (51.70%) | (44.85%) | (45.91%) |
| Return on invested capital | (154.77%) | (1,267.77%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack